All In MedTech

Device Trial Radar · NCT02142283

Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention With Trevo

Diffusion Weighted Imaging (DWI) or Computerized Tomography Perfusion (CTP) Assessment With Clinical Mismatch in the Triage of Wake Up and Late Presenting Strokes Undergoing Neurointervention (DAWN)

Last checked: Nov 19, 2026Latest source record: Jul 20, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 206 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

206

Actual

Start

Jul 2014

Primary completion

May 15, 2017

Study completion May 15, 2017

Sponsor

Lead sponsor
Stryker NeurovascularPublic (SYK)
Sponsor type
Industry
First posted
May 20, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the hypothesis that Trevo thrombectomy plus medical management leads to superior clinical outcomes at 90 days as compared to medical management alone in appropriately selected subjects experiencing an acute ischemic stroke when treatment is initiated within 6-24 hours after last seen well.

Conditions

  • Ischemic Stroke

Interventions

  • Trevo Thrombectomy ProcedureDevice

    stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)

  • Medical ManagementOther

    Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Weighted Modified Rankin Scale (mRS) Score, Lead Co-Primary Efficacy OutcomeTime frame: 90 days
  2. Functional Independence (mRS 0-2), Nested Co-Primary Efficacy OutcomeTime frame: 90 days
  3. Stroke-related Mortality, Primary Safety OutcomeTime frame: 90 days

Locations

32 sites in 5 countries. Site status is shown where the registry gives one.

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • University of California, Los Angeles

    Los Angeles, California

  • California Pacific Medical Center

    San Francisco, California

29 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.